NCT04576104View on ClinicalTrials.gov

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

June 30, 2026

Conditions
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial NeoplasiaEndometrial Carcinoma
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

DRUG

Extended Release Metformin Hydrochloride

Given PO

DRUG

Megestrol Acetate

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (8)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

55455

University of Minnesota/Masonic Cancer Center, Minneapolis

60190

Northwestern Medicine Central DuPage Hospital, Winfield

60611

Northwestern University, Chicago

90048

Cedars Sinai Medical Center, Los Angeles

80217-3364

University of Colorado, Denver

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER